BIGBEAR
PHARMACEUTICAL
Its unique characteristic is the ability to penetrate the blood-brain barrier, rendering it effective against tumors with central nervous system metastases.
AuthenticGuaranteeFast DeliveryPrivacy Roche recently announced that the EC has conditionally approved the targeted anticancer drug Rozlytrek for the treatment of pediatric and adult patien···【More】
Update: 24 Mar,2026Source: BigbearViews: 101
The European Commission (EC) has approved the targeted anticancer drug Rozlytrek (entrectinib) for the treatment of pediatric and adult patients aged ···【More】
Update: 24 Mar,2026Source: BigbearViews: 90
On June 9, 2022, Foundation Medicine announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOneCDx as a companion diagnosti···【More】
Update: 24 Mar,2026Source: BigbearViews: 91
The U.S. Food and Drug Administration (FDA) announced on October 20 that it has granted accelerated approval to Rozlytrek (entrectinib) for the treatm···【More】
Update: 24 Mar,2026Source: BigbearViews: 91
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
